On Wednesday, Sen. Rick Scott (R-Fla.) called on the Trump administration to increase tariffs on Chinese generic drug manufacturers, citing alleged forced labor practices and concerns about pharmaceutical safety.
Rick Scott Pushes Trump to Slap Tariffs on Chinese Generic Drug Makers Over 'Slave Labor' Claims
Get Abbvie Alerts
Weekly insights + SMS alerts
Scott Calls For Tariffs On Chinese Drug Makers
Scott criticized China’s pharmaceutical industry in a post on X, arguing that stronger trade measures are needed to address alleged human rights violations and protect American patients.
"We know COMMUNIST CHINA uses Uyghur SLAVE LABOR," Scott wrote.
He added, "We know they make more dangerous generic drugs than the ones we produce here. It’s unacceptable."
He further said the U.S. must act "to stop the human rights abuses and keep American patients SAFE."
Scott added that he is encouraging the Trump administration to raise tariffs on Chinese generic drug makers that he alleges are connected to these practices.
He called for accountability, writing, "These criminal thugs need to be held accountable."
US-China Pharma Trade Tensions
Last month, bipartisan U.S. lawmakers launched national security reviews into Merck & Co. Inc. (MRK) and AbbVie Inc. (ABBV) over concerns that clinical trials in China could expose sensitive U.S. biotechnology research to security and ethical risks.
Lawmakers, led by Rep. John Moolenaar, requested details on the companies’ data security, due diligence and research practices, while noting there was no evidence of wrongdoing by either company.
In 2025, China reportedly eased some trade restrictions by exempting select U.S. imports, including certain pharmaceutical products and aerospace components, from its 125% tariffs.
Chinese officials also sought feedback from businesses on other essential U.S. goods that could qualify for exemptions, with the American Chamber of Commerce in China saying several pharmaceutical companies had already benefited from the tariff relief.
More News

Stock Market Today: S&P 500, Nasdaq 100 Futures Climb as Trump Warns Iran — MRVL, AAPL, ACN in Focus

Goolsbee Warns the Fed's Inflation Patience May Be Running Out as October Hike Odds Hold Above 50%

Iran Sends War-End Terms to Trump Via Qatar — Ex-Pentagon Official Says US May Read It as 'Surrender'

Bessent Pitches US-China AI Hotline Ahead of Trump-Xi Summit: 'We Want a Shared Vision'

Intel Stock Jumps 5% Premarket: What's Fueling the Chip Giant's Rally

Apple's iPhone 18 Demand Looks 'Fine,' but This Analyst Says the Stock Is 'Relatively Rich'

Gold to $5,000? Strategist Warns a Drop to $3,000 Comes First

Super Micro Says the AI Opportunity Could Hit $4 Trillion: 'The Sky's the Limit'
Get Abbvie Alerts
Real-time alerts on price moves, news, and trading opportunities.
Join 20,000+ investors. No spam, ever.
Featured Articles
View all news
Stock Market Today: S&P 500, Nasdaq 100 Futures Climb as Trump Warns Iran — MRVL, AAPL, ACN in Focus

He Found Rolls-Royce Below $2. Now He’s Found His Second Unicorn. (Ad)

Goolsbee Warns the Fed's Inflation Patience May Be Running Out as October Hike Odds Hold Above 50%

Iran Sends War-End Terms to Trump Via Qatar — Ex-Pentagon Official Says US May Read It as 'Surrender'

Bessent Pitches US-China AI Hotline Ahead of Trump-Xi Summit: 'We Want a Shared Vision'

Intel Stock Jumps 5% Premarket: What's Fueling the Chip Giant's Rally

Apple's iPhone 18 Demand Looks 'Fine,' but This Analyst Says the Stock Is 'Relatively Rich'






